Skip to main content
For Pharma & Device Stakeholders

Claims-safe activation program measurement.

Cohort segmentation, outcome tracking, and quarterly validation. Governance rules that prevent over-claims.

What you get

Cohort Segmentation Support

Patient cohorts segmented by activation criteria, adherence patterns, and stability signals.

Activation Outcomes Tracking

Program outcomes tracked with explicit bounds and assumption disclosure.

Quarterly Validation Packets

Evidence packs formatted for program review with methodology and limits disclosed.

Governance Against Over-Claims

Built-in rules prevent reporting that exceeds what the data supports. Refusal rules enforced.

How it works

Representative workflow. Illustrative. Outcomes vary by program design.

01

Program Definition

Activation criteria, success metrics, and measurement bounds defined upfront.

02

Cohort Configuration

Patient segments configured with explicit inclusion/exclusion criteria.

03

Tracking Setup

Outcome tracking configured with assumption documentation.

04

Governance Rules

Claims-limiting rules applied to prevent unsupported conclusions.

05

Validation Delivery

Quarterly packets delivered with ranges, not point estimates.

Scope & boundaries

What we do

  • Cohort Segmentation Support
  • Activation Outcomes Tracking
  • Quarterly Validation Packets

What we don't do

  • Unsupported efficacy claims
  • Point-estimate outcomes
  • Marketing-driven metrics

Simulation ranges, not predictions. Assumptions required for all outputs.

Governance & Trust

Built for institutional requirements

Security controls, data handling practices, and scope limits are designed for procurement, legal, and security review.

Role-Based Access Control

Access scoped by role and organization. Users see only what they're authorized to access.

Tenant Isolation

Employer data is logically isolated. Cross-tenant access is structurally prevented.

Audit Logging

High-stakes actions are logged with timestamp, actor, and rationale for governance review.

Data Minimization

We collect only what's required for bounded modeling. Cohort-level inputs, not individual records where possible.

Scope & Limits

  • Simulation outputs are ranges, not predictions.
  • Not medical advice or diagnosis.
  • Assumptions required for all outputs.
  • Control design is aligned to HIPAA Security Rule safeguards and SOC 2 trust service control domains.

Change Control

Method updates are versioned, reviewed on a quarterly governance cadence, and reflected in artifact assumptions.

Evidence of value (without marketing math)

Ranges, assumptions, and limits disclosed. No invented metrics.

We don't publish customer names or results without written approval.

Instead, we show representative artifact formats and clearly-labeled illustrative scenarios.

Illustrative Scenarios

Manufacturer outcomes data scenario

Illustrative scenario
Outcomes data completeness
8095%per reporting period
Payer negotiation support
24additional data pointsper quarter

Common questions

How do you avoid making claims we can't support?

+

Governance rules are structural. The system refuses outputs that exceed what the data supports and logs the refusal.

How do we measure program lift credibly?

+

With bounded ranges, baseline comparisons, and explicit assumption disclosure. No single-point 'X% improvement' claims.

Can we use this for regulatory submissions?

+

Outputs include methodology and audit trail. Suitability for specific regulatory purposes requires your compliance review.

Ready to evaluate?

Contact us for a conservative analysis. We'll determine if bounded containment is appropriate for your context.

Simulation ranges, not predictions. Not medical advice or diagnosis.

Also see: For EmployersFor AdvisorsFor Clinics